Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics Inc (NQ: CGTX )

1.940 -0.180 (-8.49%)
Streaming Delayed Price Updated: 9:59 AM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 43,024
Open 2.120
Bid (Size) 1.940 (1)
Ask (Size) 2.010 (1)
Prev. Close 2.120
Today's Range 1.930 - 2.120
52wk Range 1.070 - 6.269
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"
From Cognition Therapeutics, Inc.
Via Globe NewsWire

Performance

YTD
-5.37%
-5.37%
1 Month
-14.16%
-14.16%
3 Month
+16.87%
+16.87%
6 Month
-29.96%
-29.96%
1 Year
-53.14%
-53.14%

More News

Read More
First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812
From Cognition Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Why Okta Shares Are Trading Higher By Around 14%; Here Are 27 Stocks Moving Premarket
Via Benzinga
Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Why Richardson Electronics Shares Surged Over 8%; Here Are 55 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series
From Cognition Therapeutics, Inc.
Via Globe NewsWire
$1.8 Million Bet On Cognition Therapeutics? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Cognition Therapeutics Announces Closing of Public Offering
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Cognition Therapeutics Announces Pricing of Public Offering
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Quanergy Systems Shares Are Trading Sharply Lower; Here Are 28 Stocks Moving Premarket
Via Benzinga
Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Why Sunlight Financial Shares Are Trading Lower By 59%, Here Are 54 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022
Via Benzinga
Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference
From Cognition Therapeutics, Inc.
Via Globe NewsWire
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.